William Horne Net Worth

William Horne biography

William E. Horne serves as Chairman of the Board of the Company. He served as the company’s CEO, expanding the homegrown organization from one facility with nine employees, to seven state-of-the-art surgery centers with more than 1,000 employees across six states, while driving annual revenues as high as $288M during his tenure. In his role as Chairman of the Board, he led the strategic direction of the company, which has made it possible for more than 75,000 patients to take back their lives from chronic pain with its minimally invasive spine procedures.

What is the salary of William Horne?

As the Chairman of the Board of H-CYTE, the total compensation of William Horne at H-CYTE is $2,372,870. There are no executives at H-CYTE getting paid more.

How old is William Horne?

William Horne is 65, he's been the Chairman of the Board of H-CYTE since 2020. There are 1 older and 7 younger executives at H-CYTE. The oldest executive at H-CYTE, Inc. is Raymond Monteleone, 72, who is the Director.

What's William Horne's mailing address?

William's mailing address filed with the SEC is 201 E KENNEDY BLVD, SUITE 700, , TAMPA,, FL, 33606.

Insiders trading at H-CYTE

Over the last 6 years, insiders at H-CYTE have traded over $0 worth of H-CYTE stock and bought 60,000 units worth $8,050 . The most active insiders traders include Todd Rfwhc Holdings, Llc Wa..., J Rex Iiifwhc Holdings, Llc..., eMichael Yurkowsky. On average, H-CYTE executives and independent directors trade stock every 286 days with the average trade being worth of $10,590,590. The most recent stock trade was executed by J Rex Iiifwhc Holdings, Llc... on 23 February 2022, trading 693,477 units of HCYT stock currently worth $6,935.

What does H-CYTE do?

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute biologics for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

H-CYTE executives and stock owners

H-CYTE executives and other stock owners filed with the SEC include:

• William Horne,
  Chairman of the Board
• Robert Greif,
  Pres
• Jeremy Daniel,
  Chief Financial Officer
• Jeremy Daniel,
  Chief Financial Officer
• Michael W. Yurkowsky,
  CEO & Director
• Michael Yurkowsky,
  Director
• Raymond Monteleone,
  Director
• Robert Greifas,
  President, Chief Executive Officer
• Dr. Tanya Rhodes Ph.D.,
  Chief Technology Officer
• Jeffery Wright CPA, CPA,
  Controller & Principal Accounting Officer
• J Rex Iiifwhc Holdings, Llc...,
  
• Todd Rfwhc Holdings, Llc Wa...,
  
• Frederick Jcfrs Investments...,
  
• Robert Smith Greif,
  Chief Executive Officer
• Todd Rfwhc Bridge, Llc Wagner,